ArticleHepatology international2026
Neutrophil extracellular traps drive cholangiocyte injury via ZNF709-TP53-MDM2 pathway in primary biliary cholangitis.
Article in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPrimary biliary cholangitis (PBC) is a chronic autoimmune liver disease in which many patients respond inadequately to ursodeoxycholic acid (UDCA) and may progress to liver failure. Although research on PBC has primarily centered on lymphocyte-mediated mechanisms, increasing evidence implicates neutrophils in autoimmunity, yet their role in PBC remains unclear.
methodsCytokine screening of patient sera collected from our medical center was performed to identify NETs-inducing factors. Transcriptomic profiling was conducted to determine the molecular effects of NETs on cholangiocytes. The therapeutic effects of the neutrophil elastase inhibitor sivelestat on NETs-associated injury were evaluated in dnTGFβRII and 2OA-BSA murine models of PBC.
resultsWe identify NETs as a critical mediator linking immune activation to biliary injury. NETs formation was markedly elevated in PBC patient samples and murine models. Exploratory cytokine profiling of patient serum samples prioritized resistin as a leading candidate mediator of NETs formation, and elevated circulating resistin levels were confirmed in an independent clinical cohort. Further analysis of patient clinical data revealed that circulating resistin levels were positively correlated with cholestasis. Transcriptomic profiling demonstrated that NETs exposure downregulated ZNF709 and activated the TP53-MDM2 pathway in cholangiocytes, leading to epithelial injury and PBC-like phenotypic changes. In vivo, treatment with sivelestat significantly reduced biliary inflammation and fibrosis, while combination therapy with UDCA produced synergistically therapeutic benefits.
conclusionsThese findings identify a resistin-NETs-ZNF709 axis that links neutrophil activation to cholangiocyte injury in PBC and suggest that targeting NETs-associated injury with sivelestat may represent a potential strategy to improve current PBC therapies.
Indexed as
Identifiers
42420744What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.